You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

中國生物製藥(01177.HK)新藥安羅替尼III期臨床試驗完成受試者入組

阿思達克 12-26 21:55
中國生物製藥(01177.HK)公布，集團正在開展一項「評價鹽酸安羅替尼膠囊聯合注射用鹽酸表柔比星對比安慰劑聯合注射用鹽酸表柔比星一線治療晚期軟組織肉瘤有效性和安全性的多中心、隨機、雙盲、平行對照III期臨床試驗」，近期已順利完成全部受試者入組。鹽酸安羅替尼膠囊是集團研發的一款多靶點受體酪氨酸激(酉每)抑制劑。
中國生物製藥(01177.HK)
20240617中國生物製藥01177
Relevant Stocks
中國生物製藥(01177.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.